ClinicalTrials.gg
Drug

Eribulin clinical trials

Also written E7389, Halaven and ER-086526.

Includes 2 studies of Liposomal Eribulin Mesylate.

studies test it
127
open now
7
in phase 3
12
first study started
2002

How each study uses eribulin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the eribulin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
15 Nov 2010 · HALAVEN · NDA 201532 (FDA, Drugs@FDA)
European Union
17 Mar 2011 · Halaven · EMEA/H/C/002084 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Eribulin Mesylate
58
Eribulin
45
B1939 Mesylate
10
Halichondrin B Analog
10
B1939
10

Brand

Halaven
44

Development codes

E7389
45
ER-086526
22
NSC-707389
1

Studies by the year they started

127 studies that test it; most in 2014 (13)

Studies that test eribulin, by start year
YearStudies
20021
20032
20042
20051
200612
20071
20082
20095
20105
201112
20129
20137
201413
20158
20163
20176
201810
20195
20202
20216
20223
20233
20243
20253
20263

By phase

A phase 1/2 study counts in both.

Early Phase 1
2
Phase 1
39
Phase 2
80
Phase 3
12
Phase 4
4
No phase
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 48 · Other 79

Eisai Inc. (29) · National Cancer Institute (NCI) (13) · Eisai Co., Ltd. (7) · Dana-Farber Cancer Institute (5) · Eisai Limited (5) · M.D. Anderson Cancer Center (4) · MedSIR (3) · Sichuan Baili Pharmaceutical Co., Ltd. (2)

Often tested with

Tested in the same studies.

Gemcitabine (7) · Capecitabine (6) · Carboplatin (5) · Vinorelbine (4) · Trastuzumab (4) · Cyclophosphamide (4) · Pembrolizumab (4) · Irinotecan (4)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 12 phase 3 studies under way

Eribulin is the comparator. A study of two new drugs counts under both.

Reaching primary completion within a year · 5

Studies that test eribulin.

Studies

Open first, then newest update. How each study uses eribulin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 127

See all 127 studies that test eribulin →

Given beside what is tested · 44 — eribulin is usual care or a partner of the new treatment

Showing 20 of 44.

As the comparator · 23 — what is tested is compared with eribulin

Showing 20 of 23.

Codes

What other systems call eribulin · ClinicalTrials.gg INT004696

  • MeSH (NLM) C490954eribulinConfirmed NLM, Wikidata
  • UNII (FDA) LR24G6354GERIBULINConfirmed FDA, NLM, Wikidata
  • RxNorm 1045453Confirmed FDA, Wikidata
  • Wikidata Q408717eribulinConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C96748EribulinOne source FDA
  • DrugBank DB08871One source Wikidata

Also registered as eribulin mesylate (UNII AV9U0660CW · RxNorm 1045452).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.